Everolimus

Generic Name: Everolimus

Brand Names: Afinitor, Votubia, Zortress

Drug Type: Small Molecule

Chemical Formula: C_₅₃H_₈₃NO_₁₄

CAS Number: 159351-69-6

Unique Ingredient Identifier: 9HW64Q8G6G

Background: Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication: Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions: Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors

Associated Therapies: -

Clinical Trials

Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation

Phase 3

Conditions: Coronary Artery Disease
Coronary Restenosis

First Posted Date: 2007-01-24

Last Posted Date: 2007-01-24

Lead Sponsor: German Heart Institute

Target Recruit Count: 484

Registration Number: NCT00426049

Locations: 🇩🇪
German Heart Institute Berlin, Berlin, Germany

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Everolimus
Drug: Trastuzumab
Drug: Paclitaxel

First Posted Date: 2007-01-24

Last Posted Date: 2015-12-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 88

Registration Number: NCT00426556

Locations: 🇺🇸
Compassionate Cancer Care Medical Group Dept.ofCCCMG, Fountain Valley, California, United States
🇺🇸
University of California at Los Angeles Dept.of UCLA Dept.ofMed., Los Angeles, California, United States
🇺🇸
Cancer Centers of the Carolinas CC of C -Eastside, Greenville, South Carolina, United States

and more 9 locations

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cisplatin
Drug: everolimus
Genetic: gene expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: biopsy

First Posted Date: 2007-01-18

Last Posted Date: 2015-05-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT00423865

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Shift to Everolimus (RAD) Kidney Sparing Study

Phase 4

Terminated

Conditions: Kidney Dysfunction
Heart Transplantation

Interventions: Drug: cyclosporine
Drug: Everolimus
Drug: Mycophenolate mofetil

First Posted Date: 2007-01-11

Last Posted Date: 2010-01-12

Lead Sponsor: University of Bologna

Target Recruit Count: 34

Registration Number: NCT00420537

Locations: 🇮🇹
Policlinico S.Orsola-Malpighi, Bologna, Italy

Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease

Phase 4

Completed

Conditions: Autosomal Dominant Polycystic Kidney Disease

Interventions: Drug: Everolimus
Drug: Placebo

First Posted Date: 2006-12-21

Last Posted Date: 2015-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 431

Registration Number: NCT00414440

Locations: 🇩🇪
Novartis Investigative Site, Würzburg, Germany

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

Phase 3

Completed

Conditions: Carcinoid Tumor
Malignant Carcinoid Syndrome

Interventions: Drug: Octreotide
Drug: Placebo
Drug: Everolimus

First Posted Date: 2006-12-15

Last Posted Date: 2014-11-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 429

Registration Number: NCT00412061

Locations: 🇺🇸
New York Oncology Hematology, P.C. Dept. of New York Oncology. PC, Albany, New York, United States
🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸
Cancer Centers of Connecticut Southington Location, Southington, Connecticut, United States

and more 36 locations